Findings

What do systematic reviews say?

1,304 questions · 1,352 findings · 210 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 230 · 17%GRADE not reported 163 · 12.1%Very low 269 · 19.9%Low 277 · 20.5%Moderate 291 · 21.5%High 122 · 9%

Pregabalin 300 mg or 600 mg vs placebo

mg pregabalin · adults with moderate or severe neuropathic pain

2 findings from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
300 participants
GRADE not reported
Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
600 participants
GRADE not reported

Pregabalin 300 mg or 600 mg vs placebo

Risk for at least one adverse event per patient · adults with moderate or severe neuropathic pain

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 3697 participants
High

Pregabalin 300 mg or 600 mg vs placebo

Serious AE · adults with moderate or severe neuropathic pain

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
17 studies · 4112 participants
High

Pregabalin 300 mg vs placebo

Lack of efficacy withdrawal · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 933 participants
High

Pregabalin 300 mg vs placebo

Somnolence · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 933 participants
Moderate

Pregabalin 300 mg vs placebo

Dizziness · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 933 participants
Moderate

Pregabalin 300 mg vs placebo

Withdrawals due to adverse events · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 933 participants
High

Pregabalin 600 mg vs placebo

Participant‐reported pain relief of 30% or greater · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 537 participants
Moderate

Pregabalin 600 mg vs placebo

Participant‐reported pain relief of 50% or greater · adults with moderate or severe pain associated with postherpetic neuralgia

1 finding from 1 review

Pregabalin for neuropathic pain in adults 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 732 participants
Moderate

Ustekinumab vs placebo

Failure to maintain remission · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in failure to maintain clinical remission compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.8 [0.63, 1.02]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.76 [0.64, 0.91]
1 study · 388 participants
Moderate

Briakinumab vs placebo

Adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.02 [0.67, 1.55]
1 study · 104 participants
Low

Briakinumab vs placebo

Serious adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.31 [0.03, 3.21]
1 study · 104 participants
Low

Briakinumab vs placebo

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.82 [0.04, 16.34]
1 study · 104 participants
Low

Ustekinumab vs placebo

Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission

Ustekinumab probably leads to lower failure to maintain clinical response compared with placebo (moderate certainty).

2 findings from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.53 [0.36, 0.79]
1 study · 145 participants
Moderate
Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.6, 0.91]
1 study · 388 participants
Moderate

Ustekinumab vs placebo

Adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.94 [0.87, 1.03]
2 studies · 541 participants
High

Ustekinumab vs placebo

Serious adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.74 [0.48, 1.15]
2 studies · 541 participants
Moderate

Ustekinumab vs placebo

Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission

Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 4.93 [0.59, 41.18]
1 study · 145 participants
Low

Briakinumab vs placebo

Failure to maintain remission · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in failure to maintain clinical remission compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.84 [0.58, 1.2]
1 study · 99 participants
Low

Briakinumab vs placebo

Failure to maintain clinical response · people with moderate to severe Crohn's disease in remission

Briakinumab showed no clear difference in failure to maintain clinical response compared with placebo (low certainty).

1 finding from 1 review

Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.64 [0.4, 1.02]
1 study · 99 participants
Low

Sublingual glucose vs oral (swallowed) glucose

Resolution of symptoms · children with hypoglycaemia associated with moderate clinical symptoms of acute malaria or moderate respiratory tract infections

The review found no eligible studies for this question.

1 finding from 1 review

First aid glucose administration routes for symptomatic hypoglycaemia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found